Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Geest, L.G. van der"'
Autor:
Jong, E.J.M. de, Janssen, Q.P., Simons, T.F.A., Besselink, M.G., Bonsing, B.A., Bouwense, S.A.W., Geurts, S.M.E., Homs, M.Y.V., Meijer, V.E. de, Tjan-Heijnen, V.C.G., Laarhoven, H.W.M. van, Valkenburg-van Iersel, L.B.J., Wilmink, J.W., Geest, L.G. van der, Koerkamp, B.G., Vos-Geelen, J. de, Dutch Pancreatic Canc Grp
Publikováno v:
the Dutch Pancreatic Cancer Group 2021, ' Real-world evidence of adjuvant gemcitabine plus capecitabine vs gemcitabine monotherapy for pancreatic ductal adenocarcinoma ', International Journal of Cancer . https://doi.org/10.1002/ijc.33916
International Journal of Cancer, 150(10), 1654-1663. Wiley
International Journal of Cancer, 150(10), 1654-1663. WILEY
International Journal of Cancer, 150(10), 1654-1663. Wiley-Liss Inc.
International Journal of Cancer. Wiley-Liss Inc.
International Journal of Cancer, 150(10), 1654-1663. Wiley
International Journal of Cancer, 150(10), 1654-1663. WILEY
International Journal of Cancer, 150(10), 1654-1663. Wiley-Liss Inc.
International Journal of Cancer. Wiley-Liss Inc.
The added value of capecitabine to adjuvant gemcitabine monotherapy (GEM) in pancreatic ductal adenocarcinoma (PDAC) was shown by the ESPAC-4 trial. Real-world data on the effectiveness of gemcitabine plus capecitabine (GEMCAP), in patients ineligibl
Autor:
Strijker, M., Veldhuisen, E. van, Geest, L.G. van der, Busch, O.R., Bijlsma, M.F., Mohammad, N.H., Homs, M.Y., Hooft, J.E. van, Verheij, J., Vos-Geelen, J. de, Wilmink, J.W., Steyerberg, W.E.W., Besselink, M.G., Laarhoven, H.W. van, Dutch Pancreatic Canc Grp
Publikováno v:
Biomarkers, 26(4), 325-334. Routledge/Taylor & Francis Group
Biomarkers, 26(4), 325-334. TAYLOR & FRANCIS LTD
Biomarkers, 26(4), 325-334. Informa Healthcare
Biomarkers
Biomarkers, 26(4), 325-334. TAYLOR & FRANCIS LTD
Biomarkers, 26(4), 325-334. Informa Healthcare
Biomarkers
BackgroundIdentification of metastatic pancreatic cancer (mPC) patients with the worst prognosis could help to tailor therapy. We evaluated readily available biomarkers for the prediction of 90-day mortality in a nationwide cohort of mPC patients.Met
Autor:
Dikken, J.L., Henneman, D., Putter, H., Lemmens, V.E.P.P., Geest, L.G. van der, Hillegersberg, R. van, Velde, C.J.H. van de, Wouters, M.W.J.M.
Publikováno v:
European Journal of Cancer, 49, S576-S576
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::d5ba03c5232dea9ce55d93849dfbbdf2
http://hdl.handle.net/1887/102305
http://hdl.handle.net/1887/102305